Last updated: July 26, 2026
Aralez Pharmaceuticals Inc. sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Vermont in 2:17-cv-00071. The case is a Hatch-Waxman patent infringement dispute tied to a generic approval/ANDA pathway and centers on whether Teva’s proposed product infringes Aralez’s Orange Book-listed patents (and whether any challenges are invalid or not infringed).
Key point for business planning: the litigation’s outcome and any settlement terms drive the earliest permissible generic launch date, the scope of design-arounds permitted, and the remaining enforceable patent estate for Aralez.
What happened in Aralez v. Teva Pharmaceuticals USA (2:17-cv-00071)?
Case posture (Hatch-Waxman track):
- Parties: Aralez Pharmaceuticals Inc. (plaintiff/patentee) vs. Teva Pharmaceuticals USA, Inc. (defendant/generic applicant).
- Docket: 2:17-cv-00071 (filed 2017; District of Vermont).
- Legal framework: patent infringement allegations typically asserted under 35 U.S.C. § 271(e)(2) for an ANDA product with an associated Paragraph IV certification or equivalent carve-out in the Orange Book.
What the complaint and infringement content usually cover in this fact pattern:
- Specific asserted patent claims listed in the Orange Book for the reference-listed drug (RLD).
- Allegations that Teva’s proposed ANDA product infringes those claims (often composition/formulation and/or method-of-use claims, depending on the Orange Book listing structure).
- Requests for relief that typically include injunction against FDA approval and sale and a finding of infringement.
Which patents were at issue in 2:17-cv-00071 and how are they typically structured?
Featured snippet answer: The patents at issue are the Orange Book-listed patents asserted by Aralez against Teva’s ANDA, generally covering either:
- Drug substance/composition (active ingredient, salt form, or formulation composition), and/or
- Drug product (formulation, dosage form, particle size, polymorph/crystal form), and/or
- Method-of-use (labeling-based therapeutic use, dosing regimen).
Typical patent categories in this dispute type:
Composition, formulation, and dosage form claims
- Salt or crystalline form dependent claims (where the RLD has a defined polymorph or hydrated state).
- Excipients and manufacturing-controlled formulation definitions.
- Release or stability-linked claim elements.
Method-of-use claims
- Therapeutic indication claims matching approved labeling.
- Dosing regimen claims that track RLD label language.
- Patient population limitations (age, indication, or comorbidity qualifiers).
Litigation consequence: these categories control how generics can design around. Formulation and method-of-use claims also determine whether skinny labels, changes in dosing, or altered formulation can avoid infringement.
What does a Paragraph IV Hatch-Waxman case mean for timing and generic entry?
Featured snippet answer: In an ANDA setting, the filing of a Paragraph IV notice can trigger an automatic 30-month stay of FDA approval, subject to the litigation schedule and outcomes. If the patentee wins or settlement bars entry, FDA approval and sales can remain blocked past the stay window.
Timeline mechanics that govern this case
- Notice/Paragraph IV: Teva’s certification (often Paragraph IV) begins the dispute.
- 30-month stay: applies if litigation is timely commenced and not resolved early in the patentee’s favor.
- Earlier resolution: summary judgment, dismissal, or trial outcomes can shorten time to entry.
- Settlement: often replaces uncertain outcomes with a defined launch date, sometimes paired with licensing terms.
How strong is Aralez’s patent estate against Teva in this dispute?
Featured snippet answer: Strength is reflected by three litigation signals that drive leverage: (1) the breadth of asserted claims, (2) claim construction positions and outcomes, and (3) whether the case reaches dispositive rulings or settles with a licensing/launch commitment.
What to look for in 2:17-cv-00071 record (high impact factors):
1) Claim construction results
- If the court adopts narrow constructions, infringement may be harder for the patentee.
- If the court adopts constructions that track Teva’s proposed ANDA product, infringement likelihood increases.
2) Infringement and invalidity defenses
- Typical invalidity vectors: obviousness, anticipation, lack of written description, enablement.
- Typical infringement vectors: non-infringement based on Teva’s composition/formulation and testing data.
3) Injunction and final judgment posture
- A final judgment of infringement supports stronger enforcement and blocks launch absent appeal or settlement.
What settlement outcomes typically appear in cases like Aralez v. Teva, and how do they affect launch?
Hatch-Waxman disputes frequently end via:
- Settlement with entry date: Teva is allowed to launch on a specific date.
- Design-around authorization: Teva can market a non-infringing version.
- Licensing: Teva pays royalties for earlier marketing.
- Dismissal with prejudice: limits future enforcement on the same Orange Book-listed patents based on the same product.
Business implication: launch timing is rarely governed solely by earliest expiration dates. Settlement terms can:
- create an earlier-than-expiration entry window, or
- keep the generic out until the “last” relevant patent expires, even if others end earlier.
What FDA and Orange Book status does this litigation tie to?
Featured snippet answer: The litigation is tied to the Orange Book patent listings for the relevant RLD. Those listings determine:
- the patents Teva certified against,
- the scope of asserted infringement,
- whether a Paragraph IV challenge was made for specific patents.
How Orange Book listings drive the legal claims
- Each Orange Book patent has its own expiry and claim scope.
- Litigation often asserts a subset of patents with the highest leverage (typically “core” composition, formulation, or method claims).
- If only some patents are asserted, other patents may still bar full entry unless waived or resolved.
What generic entry risks remain after the litigation in Aralez v. Teva?
Even if Aralez loses or the case settles, generic entry can remain constrained by:
- Unlitigated Orange Book patents for the same RLD.
- Other infringement theories not resolved in the first action (e.g., different formulation variant, different claim subset).
- Appeals (if judgment issues).
- Ongoing FDA exclusivity independent of patent status (rare in pure ANDA but possible in some RLD contexts).
How do courts typically handle design-around arguments in ANDA patent cases like this?
Featured snippet answer: Courts compare Teva’s proposed ANDA product to the asserted claim elements under claim construction. Design-around arguments often fail where:
- claimed ranges are broad,
- formulation elements are not materially changed,
- method-of-use steps still occur under the proposed label.
Design-arounds are more viable where:
- the asserted claims require a specific structural form or process parameter not matched by Teva,
- the label can be carved so the method-of-use steps do not occur.
How does 2:17-cv-00071 compare to other Aralez vs. generic cases (business pattern)?
In Aralez-style Hatch-Waxman litigation (composition/formulation or method-of-use disputes), the settlement pattern is often driven by:
- high uncertainty of trial outcomes,
- the economic value of market exclusivity,
- the cost of continued enforcement against multiple filers.
The business takeaway is that similar cases usually result in either a defined launch date or a narrow design-around that preserves the core enforceable claims.
What does the docket imply about next steps for Teva or Aralez?
The most business-relevant next steps tied to this docket format are:
- post-judgment injunction or entry permissions, if any,
- appeal deadlines if a dispositive judgment exists,
- settlement performance milestones (launch date, label carve-out, or royalty payment triggers),
- continued enforcement against other filers if the patent estate is still active.
Key litigation facts table for 2:17-cv-00071
| Item |
Value |
| Case name |
Aralez Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. |
| Docket |
2:17-cv-00071 |
| Court |
U.S. District Court, District of Vermont |
| Plaintiff |
Aralez Pharmaceuticals Inc. |
| Defendant |
Teva Pharmaceuticals USA, Inc. |
| Case type |
Hatch-Waxman patent infringement (ANDA-related) |
| Core issues |
infringement of asserted Orange Book patents; validity defenses; potential Paragraph IV framework |
| Business impact |
generic entry timing, injunction/settlement terms, remaining patent enforcement posture |
Key Takeaways
- This is a Hatch-Waxman patent infringement dispute between Aralez and Teva tied to Orange Book-listed patents covering the relevant RLD.
- The litigation’s impact is measured in generic entry timing, determined by 30-month stay mechanics, court rulings, and any settlement.
- The enforceable scope depends on which patent categories (composition/formulation vs. method-of-use) were asserted and how the court construed the claims.
FAQs
- Does a settlement in a Hatch-Waxman case automatically allow FDA approval?
- How do Orange Book “listed patents” differ from patents typically asserted in litigation?
- What claim elements most often drive infringement outcomes in formulation vs. method-of-use disputes?
- Can a generic launch before all asserted patents expire if only some patents remain in the case?
- How do label carve-outs influence method-of-use infringement risk?
References (APA)
- U.S. District Court for the District of Vermont. Aralez Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 2:17-cv-00071.
